watch
Exelixis, Inc.

Exelixis, Inc.

Sector: Commercial Physical And Biological Research Region: CA, United States


: | Nasdaq: EXEL


Exelixis, Inc. develops human therapeutics by innovating therapies for cancer and other serious diseases to various pharmaceutical product discovery and development companies. It was incorporated in November 15, 1994 and is headquartered in South San Francisco, CA.

Executives

Michael Morrissey, PhD, President and Chief Executive Officer
Michael M. Morrissey, Ph.D. has served as a director and as Exelixis’ President and Chief Executive Officer since July 2010. Dr. Morrissey has held positions of increasing responsibility at Exelixis since he joined the company in February 2000. From January 2007 until July 2010, he served as President of Research and Development, from January 2006 until December 2006, he served as Executive Vice President, Discovery, from January 2003 to December 2005, he served as Senior Vice President, Discovery, and from February 2000 through December 2002, he served as Vice President of Discovery Research. From 1991 to 2000, Dr. Morrissey held several positions at Berlex Biosciences, last holding the position of Vice President, Discovery Research. From 1986 to 1991, he served as a Senior Scientist and Project Team Leader in Medicinal Chemistry at CIBA-Geigy Corporation, a pharmaceutical company. He is the author of numerous scientific publications in medicinal chemistry and drug discovery and an inventor on 70 issued U.S. patents and 25 additional published U.S. patent applications. Dr. Morrissey holds a B.S. (Honors) in Chemistry from the University of Wisconsin and a Ph.D. in Chemistry from Harvard University.
J. Scott Garland, Executive VP and Chief Commercial Officer
Scott Garland joined Exelixis as Executive Vice President and Chief Commercial Officer in October 2011. Mr. Garland is a biotechnology and pharmaceutical industry veteran with over 20 years of experience commercializing new compounds and building franchises for approved therapies. He joined Exelixis from Genentech, where, from 2009 to 2011, he served as vice president of the Avastin franchise. From 2007 to 2009, Mr. Garland served as vice president, hematology marketing and sales at Genentech, overseeing the Rituxan franchise, and from 2002 to 2007 served in other positions of increasing responsibility at Genentech. Before joining Genentech, Mr. Garland served in positions of increasing responsibility at Amgen and Merck. Mr. Garland received his MBA from Duke University’s Fuqua School of Business, and his bachelor’s degree from California Polytechnic University (San Luis Obispo).
Frank L. Karbe, Executive VP and Chief Financial Officer
Frank L. Karbe has served as Executive Vice President and Chief Financial Officer since July 2007. From February 2004 to July 2007, Mr. Karbe served as Senior Vice President, Chief Financial Officer. From 1997 to January 2004, Mr. Karbe worked as an investment banker for Goldman Sachs & Co., where he served most recently as Vice President in the healthcare group focusing on corporate finance and mergers & acquisitions in the biotechnology industry. Prior to Goldman Sachs, Mr. Karbe held various positions in the finance department of The Royal Dutch/Shell Group in Europe. Since January 2009, Mr. Karbe has served as a member of the board of directors of Tekmira Pharmaceuticals Corporation, a publicly-held biopharmaceutical company. From July 2010 to December 2011, Mr. Karbe served as a member of the board of directors of our former subsidiary, TaconicArtemis GmbH (previously known as Artemis Pharmaceuticals GmbH). Mr. Karbe holds a Diplom Kaufmann from the WHU—Otto Beisheim Graduate School of Management, Koblenz, Germany (equivalent to a U.S. Masters of Business Administration).
Peter Lamb, PhD, EExecutive VP, Discovery Research and Chief Scientific Officer
Peter Lamb, Ph.D., has served as Executive Vice President, Discovery Research and Chief Scientific Officer since September 2009. Dr. Lamb previously served in numerous other positions since joining Exelixis in October 2000, including as Senior Director, Molecular Pharmacology and Structural Biology from October 2000 until December 2003, Vice President, Discovery Pharmacology from December 2003 until January 2007 and Senior Vice President, Discovery Research and Chief Scientific Officer from January 2007 until August 2009. From June 1992 until September 2000, Dr. Lamb held positions of increasing responsibility at Ligand Pharmaceuticals, most recently serving as Director of Transcription Research. Dr. Lamb has held post-doctoral research fellowships at the Carnegie Institution, Department of Embryology, with Dr. S.L. McKnight and the University of Oxford with Dr. N.J. Proudfoot, working in the field of gene regulation. Dr. Lamb has authored numerous articles in the fields of gene expression, signal transduction and oncology, and is an author on multiple issued and pending U.S. patents. Dr. Lamb has a Ph.D. in Molecular Biology from the ICRF/University of London and a B.A. in Biochemistry from the University of Cambridge.
Gisela M. Schwab, MD, Executive Vice President and Chief Medical
Gisela M. Schwab, M.D., has served as Executive Vice President and Chief Medical Officer since January 2008. She joined Exelixis in 2006 as Senior Vice President and Chief Medical Officer. From 2002 to 2006, she held the position of Senior Vice President and Chief Medical Officer at Abgenix, Inc., a human antibody-based drug development company. She also served as vice president, clinical development, at Abgenix from 1999 to 2001. Prior to working at Abgenix, from 1992 to 1999, she held positions of increasing responsibility at Amgen Inc., most recently as Director of Clinical Research and Hematology/Oncology Therapeutic Area Team Leader. She received her Doctor of Medicine degree from the University of Heidelberg, trained at the University of Erlangen-Nuremberg and the National Cancer Institute and is board certified in internal medicine and hematology and oncology
Pamela A. Simonton, JD, LLM, Executive Vice President and Genera
Pamela A. Simonton, J.D., LL.M., has served as Executive Vice President and General Counsel since January 2008. Previously, she served as Senior Vice President, Patents and Licensing from January 2004 until December 2007 and also as Vice President of Corporate Technology Development from April 2000 through December 2003. Prior to joining Exelixis, Ms. Simonton held positions of increasing responsibility at Bayer Corporation from July 1988 to April 2000, including Vice President of Patents and Licensing for Bayer’s Pharmaceutical Division, North America from September 1994 to July 1996 and Vice President, Licensing and Acquisitions for Bayer Corporation’s Pharmaceutical Division from July 1996 to April 2000. Ms. Simonton is admitted to practice in California (RIHC), the District of Columbia and Florida and before the United States Patent and Trademark Office. Ms. Simonton holds a B.S. in Chemistry from Barry College, an M.S. in Physics from the University of Miami, a J.D. from Nova University and an LL.M. in Patent and Trade Regulation from George Washington University.

News & Analysis